Display options
Cite
Zorofchian S, Lu G, Zhu JJ, et al. Detection of the . Front Oncol. 2018;8:382doi: 10.3389/fonc.2018.00382.
Zorofchian, S., Lu, G., Zhu, J. J., Duose, D. Y., Windham, J., Esquenazi, Y., & Ballester, L. Y. (2018). Detection of the . Frontiers in oncology, 8382. https://doi.org/10.3389/fonc.2018.00382
Zorofchian, Soheil, et al. "Detection of the ." Frontiers in oncology vol. 8 (2018): 382. doi: https://doi.org/10.3389/fonc.2018.00382
Zorofchian S, Lu G, Zhu JJ, Duose DY, Windham J, Esquenazi Y, Ballester LY. Detection of the . Front Oncol. 2018 Sep 20;8:382. doi: 10.3389/fonc.2018.00382. eCollection 2018. PMID: 30294590; PMCID: PMC6158312.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2018 Sep 20;8:382. doi: 10.3389/fonc.2018.00382. eCollection 2018.

Detection of the .

Frontiers in oncology

Soheil Zorofchian, Guangrong Lu, Jay-Jiguang Zhu, Dzifa Y Duose, Justin Windham, Yoshua Esquenazi, Leomar Y Ballester

Affiliations

  1. Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX, United States.
  2. Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center, Houston, TX, United States.
  3. Department of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, United States.

PMID: 30294590 PMCID: PMC6158312 DOI: 10.3389/fonc.2018.00382

Abstract

Primary Central Nervous System Lymphoma (PCNSL) and Metastatic (or Secondary) Central Nervous System Lymphoma (MCNSL) are rare central nervous system (CNS) malignancies that exhibit aggressive clinical behavior and have a poor prognosis. The majority of CNS lymphomas are histologically classified as diffuse large-B cell lymphoma (DLBCL). DLBCL harbors a high frequency of mutations in

Keywords: CSF; MYD88; central nervous system lymphoma; cerebrospinal fluid; digital droplet PCR; liquid biopsy

References

  1. Nat Rev Neurol. 2013 Jun;9(6):317-27 - PubMed
  2. Cancer. 2007 Oct 15;110(8):1803-14 - PubMed
  3. Hematol Oncol. 2018 Apr;36(2):429-435 - PubMed
  4. Blood. 2013 Mar 28;121(13):2522-8 - PubMed
  5. Lancet. 2003 Jan 25;361(9354):323-31 - PubMed
  6. Fluids Barriers CNS. 2011 Mar 03;8(1):14 - PubMed
  7. Radiology. 2014 Sep;272(3):843-50 - PubMed
  8. Sci Rep. 2017 May 11;7(1):1785 - PubMed
  9. Semin Radiat Oncol. 2007 Jul;17(3):223-9 - PubMed
  10. Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783 - PubMed
  11. Cancer Sci. 2018 Jan;109(1):225-230 - PubMed
  12. J Neuropathol Exp Neurol. 2018 Jul 1;77(7):628-635 - PubMed
  13. Oncotarget. 2017 Oct 24;9(12):10259-10271 - PubMed
  14. Leukemia. 2015 Mar;29(3):677-85 - PubMed
  15. Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88 - PubMed
  16. Cancer. 2002 Mar 1;94(5):1548-56 - PubMed
  17. Semin Oncol. 2009 Aug;36(4 Suppl 2):S35-45 - PubMed
  18. Blood Cancer J. 2013 Sep 06;3:e139 - PubMed
  19. Curr Treat Options Oncol. 2013 Dec;14(4):539-52 - PubMed
  20. Cancer. 1998 Feb 15;82(4):733-9 - PubMed
  21. Clin Cancer Res. 2015 Sep 1;21(17):3986-94 - PubMed
  22. Immunol Cell Biol. 2011 Aug;89(6):659-60 - PubMed
  23. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7151s-7157s - PubMed

Publication Types